Natco Pharma Limited has informed the Exchange regarding a press release dated November 18, 2021, titled "NATCO launches Tipanat tablets in India, for the treatment of advancedcolorectal and gastric cancer".
Press Release Nov 18 2021
Filed with NSE · · 3 pages · English
Summary by 6ix AI
NATCO Pharma Limited has issued a press release announcing the launch of Tipanat tablets in India for treating advanced colorectal and gastric cancer. Tipanat is a fixed-dose combination of Trifluridine and Tipiracil, marking its first introduction in the Indian market. The company emphasizes the importance of Tipanat in extending survival and improving quality of life for patients with these cancers.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from NATCO Pharma
- Natco Pharma launches Everolimus tablets 10 mg in US market
- Press Release Oct 01 2021
- Press Release Sep 02 2021
- Press Release Aug 20 2021
- Press Release Aug 03 2021
Later from NATCO Pharma
- Press Release Dec 28 2021
- NATCO Pharma receives approval for Molnupiravir Capsules 200 mg for the treatment of Covid-19 in India
- Press Release Jan 01 2022
- Press Release Jan 07 2022
- Press Release Jan 20 2022
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma